Filament Health Announces Third Quarter 2024 Financial Results …

Vancouver, British Columbia, November 14, 2024 – Filament Health Corp. (OTCQB:FLHLF) () (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development …

CouponFollow Extension

$878717
OFF

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2024 …

1 week from now

1 day ago · Q3 2024 Financial Highlights: Cash and cash equivalents of $878,717; Cash used in operating activities of $1,840,498; and. Total revenues of $426,661. Q3 2024 Operational …

newswire.ca

$878717
OFF

Filament Health Reports Third Quarter 2024 Financial Results And ...

1 week from now

1 day ago · Filament Health Corp. reported its third quarter financial results for 2024, showing cash reserves of $878,717 and total revenues of $426,661. The company used $1,840,498 in …

newsminimalist.com

94%
OFF

Filament Health Revenue Slides 94% As Cash Reserves Dwindle

1 week from now

20 hours ago · The FDA and Health Canada both cleared Phase II trials for Filament's flagship psilocybin drug candidate. Vancouver-based Filament Health Corp. (OTCQB: FLHLF) (Cboe …

greenmarketreport.com

$872048
OFF

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 …

1 week from now

May 14, 2024 · Q1 2024 Financial Highlights: Cash and cash equivalents of $872,048 and a working capital of $359,664 as of March 31, 2024 ; Cash used in operating activities of …

yahoo.com

$500
OFF

Molina Healthcare Reports Third Quarter 2024 Financial Results

1 week from now

Oct 23, 2024 · The Company purchased approximately 1.5 million shares for $500 million in the third quarter of 2024. Days in claims payable at September 30, 2024 was 48. Cash Flow. …

molinahealthcare.com

34%
OFF

Guardant Health Reports Third Quarter 2024 Financial Results And ...

1 week from now

Nov 6, 2024 · Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023. Reported 53,100 clinical tests (excluding Shield) and …

yahoo.com

12%
OFF

Aspira Women’s Health Reports Selected Third Quarter 2024

1 week from now

2 days ago · Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024. Full year 2024 cash guidance reconfirmed as $13.0-$14.5 …

nasdaq.com

$3
OFF

Jaguar Health Reports Third Quarter 2024 Financial Results

1 week from now

3 days ago · Jaguar Health Reports Third Quarter 2024 Financial Results. The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, …

businessinsider.com

FAQs about Filament Health Announces Third Quarter 2024 Financial Results … Coupon?

Where can I find more information about filament health?

Learn more at www.filament.health and on Twitter, Instagram and LinkedIn. Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2024. ...

Who is filament health?

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. ...

How much revenue was generated in the third quarter of 2024?

Revenue was $191.5 million for the third quarter of 2024, a 34% increase from $143.0 million for the corresponding prior year period. ...

What will Guardant Health expect in 2024?

Guardant Health continues to expect full year 2024 non-GAAP gross margin excluding screening to be in the range of 61% to 63% and total non-GAAP operating expenses to be in the range of $720 to $730 million, representing a flat to 1% decrease compared to 2023. ...

What did OPKO Health do in the third quarter of 2024?

MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: Completed sale of select assets of BioReference Health to Labcorp for $237.5 million. ...

What is filament's intellectual property platform?

Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at www.filament.health and on Twitter, Instagram and LinkedIn. ...